Complementary roles of 68Ga-FAPI and 18 F-FDG PET/CT in evaluating IgG4-related disease: a systematic review and pooled analysis Authors: Xue Cai, Qin Wang, Qingfan Hao, Jian Zhang Published: 2026 ABSTRACT BackgroundIgG4-related disease (IgG4-RD) lacks standardized imaging criteria. This study systematically reviewed head-to-head comparisons of 68Ga-FAPI and 18F-FDG PET/CT to clarify their complementary roles in diagnosing and staging IgG4-RD.Main bodyThree high-quality studies (n = 90) were pooled. 68Ga-FAPI showed significantly higher SUVmax and target-to-background ratios (TBR) in parenchymal organs (pancreas, salivary glands) vs. 18F-FDG (P < 0.001), offering superior lesion contrast. While 18F-FDG detected more lymph node activity, 68Ga-FAPI identified 136 vs. 78 total lesions, improving systemic burden assessment. Pathology correlated FAPI with fibrosis and FDG with inflammation, defining a “flip-flop” pattern. A FAPI/FDG ratio ≥ 1.5 predicted relapse risk.Conclusion68Ga-FAPI excels in parenchymal organ involvement, while FDG highlights inflammatory lymphadenopathy. Combining both tracers enables multimodal evaluation of fibroinflammatory activity, guiding personalized management and prognostication in IgG4-RD.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13550-026-01452-6. Background IgG4-related disease (IgG4-RD) is a rare immune-mediated fibroinflammatory condition capable of involving multiple organs, characterized by lymphoplasmacytic infiltration rich in IgG4-positive plasma cells, storiform fibrosis, and obliterative phlebitis [1].The diagnosis of IgG4-RD poses challenges and often requires a comprehensive assessment combining serology, imaging, and pathology [2].Imaging techniques are crucial for identifying involved organs, guiding biopsies, and monitoring treatment response [3].Although 18F-FDG PET/CT, a commonly used molecular imaging method, can visualize metabolically active lesions throughout the body, it is associated with issues of false negatives and false positives in IgG4-RD [4]. Recently, 68Ga-FAPI PET/CT, a novel imaging technique targeting fibroblast activation protein (FAP), has demonstrated potential in fibrotic diseases [5]. The pathological essence of IgG4-RD is immune-inflammation-driven fibrosis, wherein fibroblast activation protein (FAP) is highly expressed in activated fibroblasts and serves as a key marker of fibrotic activity.68Ga-labeled FAPI inhibitors (68Ga-FAPI), by specifically targeting FAP, allow for the direct visualization of active fibrotic regions, overcoming the metabolism-dependent limitations of FDG [6], and are characterized by high specific binding to FAP, low background noise, rapid blood clearance, and favorable biodistribution and radiation dosimetry [7]. Studies have shown that FAP is significantly upregulated in fibroblasts within IgG4-RD involved organs, particularly in the pancreas, biliary tract, and salivary glands [8]. Furthermore, FAPI PET/CT theoretically possesses the potential to distinguish active fibrosis from quiescent scars, as FAPI uptake primarily reflects the functional state of fibroblast activation [9].Theoretically, FAPI PET/CT can also assess the degree of fibrosis by quantifying FAP expression levels, providing an objective basis for disease staging [10]. Compared with FDG, FAPI exhibits a higher target-to-background ratio (TBR), showing distinct advantages especially in organs with high physiological uptake such as the liver and pancreas; notably, this comparative study primarily focused on various cancer types rather than IgG4-RD [11]. This study aims to provide robust clinical evidence for clinical selection by directly comparing (head-to-head) the lesion detection rates, uptake intensity, and image contrast of the two tracers in IgG4-RD through a systematic review and meta-analysis. Main text Materials and methods Study protocol and registration This systematic review and pooled analysis was conducted in strict accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement.The study protocol was designed to meet high methodological standards for diagnostic accuracy assessment. Search strategy and data sources We performed a comprehensive systematic literature search in three major electronic databases: PubMed, Embase, and Web of Science.The search spanned from the inception of each database to February 1, 2026. To ensure a broad and comprehensive retrieval of relevant studies, the search strategy combined Medical Subject Headings (MeSH) and free-text keywords, including but not limited to “IgG4-Related Disease,” “Fibroblast Activation Protein Inhibitor,” “FAPI,” “FDG,” and “PET/CT”.The search was restricted to articles published in English.We refined the search results using Boolean operators (AND, OR).The complete electronic search strings for each database, including all Boolean operators and field tags, are provided in the Supplementary Material (Table S1). Inclusion criteria and study selection The inclusion criteria were structured according to the PICO (Population, Index test, Comparator, and Outcomes) framework: Population: Patients with histopathologically or clinically confirmed IgG4-RD.Index Test: 68Ga-FAPI PET/CT.Comparator: 18 F-FDG PET/CT (head-to-head comparison).Outcomes: Studies reporting at least one quantitative metric (e.g., SUVmax, TBR) or lesion detection rates for both tracers.Study Design: Prospective or retrospective comparative studies; case reports and reviews were excluded. Population: Patients with histopathologically or clinically confirmed IgG4-RD. Population: Patients with histopathologically or clinically confirmed IgG4-RD. Index Test: 68Ga-FAPI PET/CT. Index Test: 68Ga-FAPI PET/CT. Comparator: 18 F-FDG PET/CT (head-to-head comparison). Comparator: 18 F-FDG PET/CT (head-to-head comparison). Outcomes: Studies reporting at least one quantitative metric (e.g., SUVmax, TBR) or lesion detection rates for both tracers. Outcomes: Studies reporting at least one quantitative metric (e.g., SUVmax, TBR) or lesion detection rates for both tracers. Study Design: Prospective or retrospective comparative studies; case reports and reviews were excluded. Study Design: Prospective or retrospective comparative studies; case reports and reviews were excluded. Data extraction and quality assessment Literature screening and data extraction were independently performed by two investigators (Q.F.H. and X.C.).Any discrepancies regarding study inclusion or data extraction were resolved through consensus via group discussion or, if necessary, consultation with a third senior reviewer.The methodological quality and potential risk of bias of the included studies were rigorously assessed using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2), the recommended standard tool for diagnostic accuracy evaluation. Statistical analysis All statistical analyses and graph plotting were performed using GraphPad Prism software (Version 9.0, GraphPad Software, San Diego, CA, USA). Continuous variables (such as maximum standardized uptake value [SUVmax] and target-to-background ratio [TBR]) were expressed as mean ± standard deviation (SD).Differences in quantitative uptake values between 68Ga-FAPI and 18F-FDG were evaluated using the paired Student’s t-test or Wilcoxon matched-pairs signed-rank test, depending on the normality of the data distribution.In the assessment of lesion detection capability, categorical data were expressed as frequencies (n) and percentages (%). Differences in lesion detection rates between the two tracers were analyzed using the Chi-square test or Fisher’s exact test. A P-value of less than 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Results Literature search results The initial search identified a total of 169 relevant articles across the three major databases (PubMed, Embase, and Web of Science).After automatic de-duplication using reference management software supplemented by manual verification, 70 duplicate records were removed, leaving 99 articles for the preliminary screening phase.Following a rigorous screening of titles and abstracts, the majority of articles unrelated to the study topic, reviews, case reports, and animal studies were excluded, leaving 17 articles for full-text assessment.Through careful reading and strict review of the full texts, studies with non-head-to-head comparison designs, lack of key quantitative data, or overlapping patient cohorts were further excluded. Finally, a total of 3 high-quality studies meeting all inclusion and exclusion criteria (Luo et al., Liu et al., Schmidkonz et al.) were included in this systematic review and pooled analysis.The detailed literature screening and inclusion process is shown in (Fig. 1). Fig. 1PRISMA 2020 flow diagram illustrating the literature search and study selection process PRISMA 2020 flow diagram illustrating the literature search and study selection process Methodological quality assessment The risk of bias and applicability of the 3 included studies (Luo et al., Liu et al., Schmidkonz et al.) were assessed using the QUADAS-2 tool, with results indicating a high overall methodological quality of the included studies (Fig. 2 ). Fig. 2Summary of the methodological quality of the included studies according to the QUADAS-2 tool Summary of the methodological quality of the included studies according to the QUADAS-2 tool In the “Patient Selection” domain, all studies explicitly described inclusion criteria and avoided case-control design bias, thus being rated as low risk.In the “Index Test” and “Reference Standard” domains, as all patients underwent head-to-head comparisons of 68Ga-FAPI and 18F-FDG PET/CT within a short interval, and diagnostic results were referenced against histopathology or clinical follow-up with proper blinding, no significant measurement bias was detected.Additionally, no attrition or inappropriate exclusion was observed in any study regarding “Flow and Timing”. In summary, all included studies were evaluated as “Low Risk” in terms of bias risk and clinical applicability, with no “High Risk” or “Unclear” items found, indicating a robust and reliable evidentiary basis for this systematic review. Study characteristics and baseline data The 3 studies finally included in this systematic review and pooled analysis (Luo et al., Liu et al., Schmidkonz et al.) comprised a total of 90 patients with histopathologically or clinically confirmed IgG4-related disease (IgG4-RD).All patients completed head-to-head comparisons of 68Ga-FAPI and 18F-FDG PET/CT within a short time interval.Among these 3 studies, one was a prospective cohort design (Luo et al., [8]), and two were retrospective comparative studies (Liu et al., [35]; Schmidkonz et al., [36]).The study locations were distributed in China (2 studies) and Germany (1 study), representing data from Asian and European populations, respectively.The median age of patients ranged from 58 to 61 years, with a higher proportion of male patients than females (male: female ratio approximately 2:1), consistent with the epidemiological characteristics of IgG4-RD.The study by Liu et al. further subdivided patients into proliferative and fibrotic subgroups. Detailed baseline characteristics of the included studies are presented in (Table 1 ). Table 1Baseline information of comparative studies enrolled in the meta-analysisReferencesCountryYearDesignPatientsImaging examinationsAgeNo. of patientsLuo et al. [8]China2020Prospective cohort studyHistopathologically or clinically diagnosed IgG4-RD68Ga-FAPI-04 PET/CT18F-FDG PET/CTMedian age 61(range 35–78)26 (19 m; 7 f)Liu et al. [35]China2025Comparative studyNewly diagnosed IgG4-RD (Proliferative & Fibrotic subtypes)68Ga-FAPI-04 PET/CT18F-FDG PET/CTMedian age 58(range 31–82)37 (25 m; 12 f)Schmidkonz et al. [36]Germany2020Comparative studyIgG4-RD patients with histopathological confirmation68Ga-FAPI-04 PET/CT18F-FDG PET/CTMedian age 60(range 40–80)27 (18 m; 9 f) Table 1Baseline information of comparative studies enrolled in the meta-analysisReferencesCountryYearDesignPatientsImaging examinationsAgeNo. of patientsLuo et al. [8]China2020Prospective cohort studyHistopathologically or clinically diagnosed IgG4-RD68Ga-FAPI-04 PET/CT18F-FDG PET/CTMedian age 61(range 35–78)26 (19 m; 7 f)Liu et al. [35]China2025Comparative studyNewly diagnosed IgG4-RD (Proliferative & Fibrotic subtypes)68Ga-FAPI-04 PET/CT18F-FDG PET/CTMedian age 58(range 31–82)37 (25 m; 12 f)Schmidkonz et al. [36]Germany2020Comparative studyIgG4-RD patients with histopathological confirmation68Ga-FAPI-04 PET/CT18F-FDG PET/CTMedian age 60(range 40–80)27 (18 m; 9 f) Baseline information of comparative studies enrolled in the meta-analysis 68Ga-FAPI-04 PET/CT 18F-FDG PET/CT Median age 61 (range 35–78) 68Ga-FAPI-04 PET/CT 18F-FDG PET/CT Median age 58 (range 31–82) 68Ga-FAPI-04 PET/CT 18F-FDG PET/CT Median age 60 (range 40–80) Data pooled analysis Although this systematic review included 3 studies with 90 patients, due to differences in data reporting formats, only 2 studies (Luo et al. and Liu et al., totaling 63 patients) provided compatible Mean ± SD data and were thus included in the quantitative pooled analysis (Meta-analysis) for SUVmax.The study by Schmidkonz et al. (n = 27), which reported only medians and ranges, could not be directly statistically pooled and was therefore included only for qualitative description, excluded from quantitative graphical analysis.Given the small number of included studies, we employed a sample-size weighted mean to calculate the pooled SUVmax and TBR.(Fig. 3). Fig. 3Head-to-head comparison of quantitative parameters. Note: These quantitative results are based on the pooled data from two compatible studies (Luo et al. and Liu et al., n = 63). Panel A shows that 68Ga-FAPI tends to exhibit higher SUVmax values than 18F-FDG in the pancreas and salivary glands (P < 0.001). Panel B demonstrates that 68Ga-FAPI yields preliminarily higher target-to-background ratios (TBR) in the pancreas and salivary glands (P < 0.001), suggesting superior lesion-to-background contrast. Panel C reveals that 68Ga-FAPI detected more lesions than 18F-FDG in the reported cohort (P < 0.001). Given the limited number of studies, these statistical differences should be interpreted as preliminary findings Head-to-head comparison of quantitative parameters. Note: These quantitative results are based on the pooled data from two compatible studies (Luo et al. and Liu et al., n = 63). Panel A shows that 68Ga-FAPI tends to exhibit higher SUVmax values than 18F-FDG in the pancreas and salivary glands (P < 0.001). Panel B demonstrates that 68Ga-FAPI yields preliminarily higher target-to-background ratios (TBR) in the pancreas and salivary glands (P < 0.001), suggesting superior lesion-to-background contrast. Panel C reveals that 68Ga-FAPI detected more lesions than 18F-FDG in the reported cohort (P < 0.001). Given the limited number of studies, these statistical differences should be interpreted as preliminary findings Semi-quantitative uptake intensity Pooled analysis based on the two mergeable head-to-head comparative studies (Luo et al. and Liu et al., totaling 63 patients) revealed significant differences in the uptake patterns of 68Ga-FAPI and 18F-FDG across different involved organs (Fig. 3-A).In involved pancreatic parenchyma, the mean SUVmax of 68Ga-FAPI was significantly higher than that of 18F-FDG (P < 0.001), indicating that FAPI possesses higher activity in reflecting pancreatic fibroinflammation.Similarly, in submandibular/parotid gland lesions, 68Ga-FAPI also exhibited significantly higher radiotracer uptake (P < 0.001).However, an opposite trend was observed in lymph node lesions: the uptake value of 18F-FDG was significantly higher than that of 68Ga-FAPI (P < 0.001).This organ-specific “flip-flop phenomenon” suggests that the two tracers may reflect the metabolic characteristics of different pathological components (inflammation vs. fibrosis) of IgG4-RD. Lesion detection capability In the assessment of lesion detection capability, 68Ga-FAPI demonstrated sensitivity superior to that of 18F-FDG (Fig. 3-C).Based on data analysis from a representative study (Luo et al.), 68Ga-FAPI PET/CT detected a total of 136 IgG4-RD-related lesions, whereas concurrent 18F-FDG PET/CT detected only 78 lesions.The overall lesion detection rate of 68Ga-FAPI was significantly higher than that of 18F-FDG (P < 0.001). 68Ga-FAPI was able to identify more involved organs missed by 18F-FDG, with particularly evident detection advantages in pancreatic, biliary, and certain retroperitoneal fibrosis lesions, thereby more accurately assessing the pan-scan extent of the disease. Image contrast and target-to-background ratio (TBR) To evaluate image quality and lesion visualization, we compared the target-to-background ratio (TBR) of the two tracers (Fig. 3-B).Benefiting from extremely low abdominal background uptake, 68Ga-FAPI demonstrated superior image contrast in parenchymal organs. In pancreatic lesions, the mean TBR of 68Ga-FAPI reached 18.02 ± 13.91, which was more than 5 times that of 18F-FDG (3.44 ± 2.05), a difference of high statistical significance (P < 0.001).Similarly, in salivary gland lesions, the TBR of 68Ga-FAPI (9.92 ± 5.61) was significantly higher than that of 18F-FDG (3.12 ± 1.51, P < 0.001).These results indicate that 68Ga-FAPI provides a higher signal-to-noise ratio, rendering lesion boundaries clearer and facilitating the identification of small lesions. Heterogeneity in treatment response monitoring Given the limited longitudinal follow-up data available (exclusively from the study by Schmidkonz et al.), the following findings should be interpreted as qualitative and hypothesis-generating observations rather than generalizable conclusions. Based on the analysis of longitudinal follow-up data from the study by Schmidkonz et al., the two tracers exhibited significant biological differences in assessing treatment response.Following anti-inflammatory therapy (e.g., rituximab or glucocorticoids), the vast majority of lesions with high baseline uptake showed a significant reduction or even disappearance of metabolic activity on 18F-FDG PET/CT, suggesting effective control of inflammatory infiltration.However, within the same group of lesions, 68Ga-FAPI radiotracer uptake showed varying degrees of persistence after treatment; in some involved organs (particularly the pancreas and retroperitoneal regions), the FAPI signal remained at a relatively high level despite some attenuation.This phenomenon of “FDG-negative but FAPI-persistent” was corroborated at the immunofluorescence level, indicating that while treatment successfully cleared or suppressed lymphocytes (CD45+), it failed to fully reverse activated fibroblasts (FAP+) and the associated fibrotic remodeling process. Discussion Pathophysiological mechanisms of FAPI advantages The diagnostic utility of 68Ga-FAPI PET/CT stems from its specific targeting of activated fibroblasts through binding to the catalytic site of FAP [12, 13]. This superior ability to identify active fibrosis has been documented across various fibroinflammatory conditions, including Crohn’s disease [14], supporting its potential for mapping the matrix remodeling process in IgG4-RD [15]. Since IgG4-RD progression involves a synergistic interplay between immune dysregulation and fibrosis [16], FAPI can uniquely capture early inflammation-associated fibrosis and quantify fibrotic burden in late-stage disease to guide corticosteroid therapy [9]. This is corroborated by research from Mori et al. [17], who found that FAPI uptake significantly correlates with histological fibrosis grading. A representative clinical example is IgG4-related pancreatitis, where FAPI identifies fibrosis-dominant lesions that show only mild activity on metabolism-dependent 18F-FDG PET/CT [18].A critical advantage of FAPI is its characteristically low physiological background in organs such as the brain, liver, and urinary system [19–22]. By minimizing interference in the salivary glands and gastrointestinal tract compared to FDG [12], FAPI significantly enhances the target-to-background ratio (TBR) for detecting occult IgG4-RD lesions. This advantage is particularly pronounced in abdominal assessments, where FAPI resolves the diagnostic ambiguity caused by physiological 18F-FDG uptake in the pancreas and adjacent intestines [23]. In hepatobiliary involvement, the low hepatic background of FAPI enables clearer lesion demarcation than FDG [24], thereby improving the overall diagnostic accuracy and contrast for multisystem IgG4-RD involvement. Discussion on the “Flip-flop phenomenon As immune organs, the physiological structure of lymph nodes and the dynamic changes in cellular composition (such as lymphocytes, macrophages, CAFs) under pathological conditions directly affect the distribution and signal characteristics of FDG and FAPI, resulting in the “flip-flop phenomenon”—where the uptake patterns of FDG and FAPI in benign versus malignant lymph nodes may be opposite or complementary [25].Anatomically, the lymph node stromal network, particularly FRCs, typically exhibits minimal FAP expression under steady-state conditions, which aligns with the low baseline FAPI uptake observed in non-involved nodes [26, 27].When lymph nodes encounter antigenic stimulation (e.g., infection, tumor antigens), reactive hyperplastic lymph nodes show significantly increased 18F-FDG uptake, often exhibiting a diffuse, symmetrical distribution, which is a major source of false positives [28].Studies show that in chronic inflammation or autoimmune diseases (e.g., rheumatoid arthritis, sarcoidosis, systemic sclerosis), involved lymph nodes can present with diffuse high FDG uptake, forming the basis for FDG positivity in the so-called “flip-flop phenomenon” [29].In metastatic lymph nodes, in addition to the stromal reaction induced by tumor cells themselves (inducing host fibroblast conversion to CAFs), CAFs infiltrating the metastatic foci also abundantly express FAP.FAP expression levels become key to distinguishing benign from malignant lymph nodes: reactive hyperplasia (acute inflammation) typically has low FAP expression, while metastatic lymph nodes (especially epithelial tumor metastases) have high FAP expression due to CAF richness [30]. Therefore, the “flip-flop phenomenon” in lymph node assessment implies that under specific pathological conditions, 18F-FDG PET/CT and FAPI PET/CT may present opposite or complementary signal patterns for determining the benign or malignant nature of the same lymph node. FDG-PET effectively assesses IgG4-RD activity and organ involvement, particularly in lymph nodes. Involved lymph nodes show high FDG uptake with an average SUVmax of 4.0 to 7.0 [31]. FDG accumulates in activated immune cells, reflecting the characteristic lymphoplasmacytic infiltration [32]. A multicenter study demonstrated that FDG-PET sensitivity exceeds 90% for detecting involved nodes, especially in mediastinal and hilar regions [4]. This sensitivity is superior to CT or MRI [4]. For instance, a case report showed high FDG uptake (SUVmax > 6) in the spleen and lymph nodes of an IgG4-RD patient [33]. In contrast, FAPI-PET often shows low uptake in lymph nodes. The SUVmax of FAPI in these nodes is generally lower than that of FDG [34]. This reflects the absence of significant storiform fibrosis in lymph nodes, which are instead dominated by lymphoid follicular hyperplasia. Consequently, FAP-positive fibroblasts are insufficient for high tracer accumulation. Luo et al. confirmed that involved lymph nodes show high FDG uptake but no FAPI accumulation [8]. Disease subtypes also influence FAP expression [35]. Proliferative types show significantly higher FAPI uptake than fibrotic types (SUVmax 17.67 vs. 10.93) [35]. Furthermore, cytokines in the early inflammatory stage may inhibit fibroblast activation, leading to lower FAPI signals [36]. Schmidkonz et al. [36] directly validated the “separation of inflammation and fibrosis” pathologically. Immunofluorescence analysis showed that 18 F-FDG uptake correlates with the density of CD45 + lymphoplasmacytes. Conversely, 68Ga-FAPI uptake specifically corresponds to FAP+/Vimentin+ activated fibroblasts [36]. These different mechanisms lead to divergent results during treatment monitoring. After anti-inflammatory therapy, FDG uptake decreases as inflammation subsides. However, FAPI signals persist in some lesions, revealing residual fibrotic activity. This provides a biological foundation for using FAPI to monitor clinical efficacy. Clinical translational significance of FAPI PET in IgG4-RD FAPI PET is a precise tool for IgG4-RD diagnosis and assessment. It targets activated fibroblasts to improve disease staging. 18 F-FDG PET/CT has limitations due to high physiological background and metabolic overlap [37]. FAPI PET targets FAP, which is highly expressed in activated fibroblasts [12]. This results in low background signals and superior contrast. FAPI PET often detects involved organs missed by FDG or conventional imaging. For example, FAPI PET identified lacrimal gland involvement not seen on FDG [38]. This finding influenced clinical staging and treatment [38]. Another study showed that PET/CT detected 50% more involved organs than physical examination, ultrasound, or CT [10]. Furthermore, FAPI PET distinguishes between proliferative and fibrotic subtypes [35]. Proliferative IgG4-RD involves inflammatory infiltration, while the fibrotic type shows significant fibrosis. These subtypes differ in treatment response and prognosis. FDG PET often fails to differentiate them. However, FAPI uptake is significantly higher in proliferative lesions (SUVmax: 17.67) than in fibrotic lesions (SUVmax: 10.93) [35]. The target-to-background ratio is also higher (15.49 vs. 9.25) [35]. The “PET index” (FAPI SUVmean / FDG SUVmean) further quantifies fibroinflammatory activity [35]. This index is higher in proliferative cases (1.46 vs. 1.14) [35]. Relying only on FDG may lead to misjudging active fibrosis as stable disease. Changes in FAPI uptake serve as biomarkers for fibrosis reversal or progression. Preclinical studies support this concept [39]. In mouse models of pulmonary fibrosis, FAPI uptake decreased significantly after anti-fibrotic treatment [39]. This reduction correlated with histological changes [39]. Thus, FAPI PET can track treatment response accurately. In IgG4-RD, periodic FAPI PET monitors anti-fibrotic therapy through SUVmax, TBR, or total load (TL-FAPI). A sustained reduction in uptake predicts fibrotic regression. This is crucial for assessing long-term prognosis. Additionally, a PET index > 1.5 indicates a high recurrence risk. FAPI PET serves as a prognostic biomarker to guide maintenance therapy [35]. Limitations This study has certain limitations.First, due to the low incidence of IgG4-RD and the fact that FAPI imaging technology is still in the clinical dissemination phase, the number of head-to-head comparative studies meeting inclusion criteria was limited (only 3), with a small overall sample size (n = 90).This limited the statistical power to conduct more in-depth subgroup analyses (e.g., different organ subgroups or different fibrosis stages).Second, significant heterogeneity existed among the included studies; some were of retrospective design, which may introduce selection bias.Additionally, although all patients had a definitive diagnosis, it was practically difficult to histopathologically verify every PET/CT-positive lesion; the characterization of some small lesions relied on clinical follow-up, which may introduce some bias in the assessment of diagnostic efficacy.Finally, this study mainly focused on a cross-sectional comparison of diagnostic efficacy and lacked longitudinal data regarding FAPI in monitoring treatment response and long-term prognostic assessment, which still requires further verification by future large-sample, multicenter prospective studies.Future multi-center prospective studies with larger cohorts and standardized quantitative metrics are warranted to confirm these preliminary findings and to establish the long-term prognostic value of FAPI PET/CT in monitoring treatment-induced fibrosis reversal. Conclusion In summary, this systematic review and pooled analysis demonstrates that 68Ga-FAPI PET/CT possesses unique clinical value in the diagnosis and assessment of IgG4-related disease (IgG4-RD).Benefiting from its specific targeting mechanism for fibroblast activation protein (FAP) and extremely low abdominal physiological background uptake, 68Ga-FAPI exhibits sensitivity and image contrast significantly superior to traditional 18F-FDG PET/CT in detecting parenchymal organ involvement, such as in the pancreas, bile ducts, and salivary glands.However, in the assessment of lymph node lesions, 18F-FDG retains an irreplaceable advantage.This finding suggests that the two tracers reflect different pathophysiological processes of IgG4-RD—fibrotic activity and inflammatory cell infiltration, respectively—indicating that they are not simple substitutes for each other but rather complementary in clinical application.68Ga-FAPI holds promise as a powerful complementary imaging tool, particularly suitable for characterizing fibrosis-dominant lesions, detecting small occult lesions, and accurately staging the systemic extent of the disease. Supplementary material Supplementary material 1. Supplementary material 1. Supplementary material 2. Supplementary material 2.